Hansa Biopharma AB (HNSA) Price & Analysis

Compare

0 Followers

HNSA Stock Chart & Stats

Day’s Range― - ―

52-Week Rangekr19.58 - kr57.30

Previous CloseN/A

Volume97.73K

Average Volume (3M)120.70K

Market Cap

kr1.60B

Enterprise Valuekr3.18B

Total Cash (Recent Filing)kr250.20M

Total Debt (Recent Filing)kr1.02B

Price to Earnings (P/E)―

Beta0.05

Next Earnings

Jul 17, 2025

EPS Estimate

-1.86

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.55

Shares Outstanding67,814,240

10 Day Avg. Volume91,083

30 Day Avg. Volume120,699

Financial Highlights & Ratios

PEG Ratio-0.24

Price to Book (P/B)5.96

Price to Sales (P/S)0.00

P/FCF Ratio-9.92

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

kr143.00

Price Target Upside504.91% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Hansa Biopharma AB News

PremiumCompany Announcements

Hansa Biopharma Raises SEK 232 Million and Restructures Debt to Support Growth

2d ago

PremiumCompany Announcements

Hansa Biopharma Announces Directed Share Issue and Debt Restructuring

2d ago

PremiumRatings

Hansa Biopharma’s Imlifidase Shows Promising Developments in GBS Treatment, Earning Buy Rating from Analyst

3d ago

PremiumCompany Announcements

Hansa Biopharma’s CEO to Speak at BIO International Convention

9d ago

PremiumCompany Announcements

Hansa Biopharma to Host Virtual Investor Event on Guillain-Barré Syndrome

11d ago

PremiumCompany Announcements

Hansa Biopharma Announces Strategic Restructuring for Enhanced Efficiency

25d ago

PremiumCompany Announcements

Hansa Biopharma Announces Annual General Meeting for June 2025

25d ago

PremiumCompany Announcements

Hansa Biopharma’s Imlifidase Shows Promise in Treating Guillain-Barré Syndrome

1M ago

See All SE:HNSA News

See All News >

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressThe completion of patient enrollment in the pivotal Phase 3 trial for anti-GBM disease is ahead of schedule, highlighting the company's progress and the unmet needs in the autoimmune space.

Market ExpansionReimbursement is now available in major cities such as Barcelona and Madrid, which should increase patient access.

Strategic LeadershipThe company's strategic planning and execution are expected to improve under the new CEO, which is crucial for the development of HNSA-5487.

Bears Say

Financial ChallengesThe company has capital needs that exceed current cash balance.

Regulatory ApprovalImlifidase only has conditional approval in the EU and no US approval.

Reimbursement ConcernsThe high cost of imlifidase may cause payors to resist coverage.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

<0.01%

Mutual Funds

― Other Institutional Investors

99.74% Public Companies and

Individual Investors

Detailed Ownership Overview >

HNSA FAQ

What was Hansa Biopharma’s price range in the past 12 months?

Hansa Biopharma lowest stock price was kr19.58 and its highest was kr57.30 in the past 12 months.

What is Hansa Biopharma’s market cap?

Hansa Biopharma’s market cap is kr1.60B.

When is Hansa Biopharma’s upcoming earnings report date?

Hansa Biopharma’s upcoming earnings report date is Jul 17, 2025 which is in 27 days.

How were Hansa Biopharma’s earnings last quarter?

Hansa Biopharma released its earnings results on Apr 24, 2025. The company reported -kr0.55 earnings per share for the quarter, beating the consensus estimate of -kr2.673 by kr2.123.

Is Hansa Biopharma overvalued?

According to Wall Street analysts Hansa Biopharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Hansa Biopharma pay dividends?

Hansa Biopharma does not currently pay dividends.

What is Hansa Biopharma’s EPS estimate?

Hansa Biopharma’s EPS estimate is -1.86.

How many shares outstanding does Hansa Biopharma have?

Hansa Biopharma has 67,814,240 shares outstanding.

What happened to Hansa Biopharma’s price movement after its last earnings report?

Hansa Biopharma reported an EPS of -kr0.55 in its last earnings report, beating expectations of -kr2.673. Following the earnings report the stock price went up 6.188%.

Which hedge fund is a major shareholder of Hansa Biopharma?

Currently, no hedge funds are holding shares in SE:HNSA

Company Description

Hansa Biopharma

Hansa Biopharma AB (HNSA) is a leading biopharmaceutical company based in Sweden, focused on developing innovative immunomodulatory treatments for rare immunologic diseases. The company operates within the healthcare and biotechnology sectors, specializing in enzyme technology to address unmet medical needs. Its core product, Idefirix® (imlifidase), is designed to inactivate IgG antibodies, facilitating life-saving organ transplants in highly sensitized patients.

HNSA Stock 12 Month Forecast

Average Price Target

kr143.00

▲(504.91%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"kr21","144":"kr144","51.75":"kr51.8","82.5":"kr82.5","113.25":"kr113.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr143.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr143.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr143.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,51.75,82.5,113.25,144],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"Jul<br/>2024","9":"Dec<br/>2024","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.12,32.34153846153846,41.56307692307692,50.784615384615385,60.00615384615385,69.22769230769231,78.44923076923077,87.67076923076924,96.8923076923077,106.11384615384615,115.33538461538461,124.55692307692308,133.77846153846153,{"y":143,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.12,32.34153846153846,41.56307692307692,50.784615384615385,60.00615384615385,69.22769230769231,78.44923076923077,87.67076923076924,96.8923076923077,106.11384615384615,115.33538461538461,124.55692307692308,133.77846153846153,{"y":143,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.12,32.34153846153846,41.56307692307692,50.784615384615385,60.00615384615385,69.22769230769231,78.44923076923077,87.67076923076924,96.8923076923077,106.11384615384615,115.33538461538461,124.55692307692308,133.77846153846153,{"y":143,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":43.46,"date":1688169600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.24,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.5,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.1,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.64,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.95,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.56,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.52,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >